Citiraj:
The lack of a large number of adequately designed
prospective randomized trials and inconsistency in inclusion
criteria makes it extremely difficult to conclusively
demonstrate an advantage of a single protocol for all poor
responders. Evidence would suggest that minimizing
GnRHa doses would be advantageous. The use of GnRHant
in this patient population has not been demonstrated to be
consistently beneficial although the use of adjuvant
estrogen priming may be of help.
Ovdje se recimo govori da je kod low respondera učinkovitiji GnRH agonist (što je supresija prije stimulacije) u malim dozama, a ne vidi se neka povećana korist od GnRH antagonista (što su cetrotide). Čak kaže da je postutak trudnoća uz korištenje ovih drugih bila manja. Hm ... tko bi ga znao :/ :?